3.55k followers • 19 symbols -0.39% Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
The " Fast Money " traders shared their first moves for the market open. Steve Grasso was a buyer of the Utilities ETF XLU . Karen Finerman was a buyer of JPMorgan JPM . Dan Nathan was a seller of Costco COST .
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Zacks.com featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive
Bristol-Myers Squibb (BMY) closed at $53.64 in the latest trading session, marking a +0.37% move from the prior day.
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Following what the majority of brokers are saying about a particular stock can help understand its potential. Hence, when a broker upgrades a stock, one can easily rely on it.
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
A former Insys Therapeutics Inc sales representative now married to the drugmaker's ex-CEO said on Wednesday she arranged to have a physician assistant in New Hampshire receive kickbacks to prescribe patients its addictive fentanyl spray. The testimony came at the start of the trial in federal court in Concord, New Hampshire, of Christopher Clough, a physician assistant who prosecutors say accepted nearly $50,000 from Insys in exchange for prescribing its powerful opioid pain drug, Subsys. The trial could provide a glimpse into some of the evidence prosecutors will use in next month's trial of six former Insys executives and managers, including John Kapoor, a onetime billionaire who was the company's founder and chairman.
A former physician assistant in New Hampshire put his own greed ahead of medical obligations by taking kickbacks from Insys Therapeutics Inc to prescribe patients its highly addictive fentanyl spray, a federal prosecutor said on Wednesday. Assistant U.S. Attorney Seth Aframe told a federal jury in Concord, New Hampshire, at the start of a trial that the kickbacks to Christopher Clough, 45, were part of the Arizona drugmaker's overall effort to boost sales of its opioid, Subsys.
Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Today, we look at a slightly riskier part of the sector in promising small caps that should be able to reach profitability with little to no additional funding needs. Revenues should more than double this year to over $140 million as the genetic test market continues to expand rapidly and Invitae garners market share. The company is doing a good job lessening its cash burn every quarter and is on the path to reach profitability late in 2019.
A former physician assistant is set to face trial in New Hampshire on Wednesday over charges he accepted kickbacks from Insys Therapeutics Inc to prescribe a highly addictive fentanyl spray the drugmaker produced. A federal jury in Concord, New Hampshire, will hear opening statements in the trial of Christopher Clough, whose case could provide a glimpse into some of the evidence prosecutors plan to use in the upcoming trial of six former Insys executives and managers. Both cases stem from what prosecutors say was a wide-ranging scheme overseen by Insys executives including John Kapoor, a onetime billionaire who was its founder and chairman, to pay medical practitioners kickbacks to prescribe its powerful opioid, Subsys.
How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.
Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.
How's Seattle Genetics Positioned? Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
In 2011 Mark Baker was appointed CEO of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...
Rising bond yields are creating new opportunities for income-seeking investors, but some companies are sweetening their payouts as well.
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.